| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/14/2004 | EP1406514A1 Enteral formulations |
| 04/14/2004 | EP1406513A1 Protein-containing foodstuff comprising a cross-linking enzyme and a hydrocolloid |
| 04/14/2004 | EP1406507A1 Methods of extracting casein fractions from milk and caseinates and production of novel products |
| 04/14/2004 | EP1406493A1 Administration of agents via the pept-2 transporter |
| 04/14/2004 | EP1351696A4 Composition for delivery of hematopoietic growth factor |
| 04/14/2004 | EP1259617B1 Bunyaviridal reaper proteins and uses therefor |
| 04/14/2004 | EP1181038B1 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals |
| 04/14/2004 | EP1137432B1 Use of protein c for the treatment of thrombocytopenic purpura and hemolytic uremic syndrome |
| 04/14/2004 | EP1121426B1 Method for triggering apoptosis in cells |
| 04/14/2004 | EP1021541B1 Amino-terminally truncated mcp-2 as chemokine antagonists |
| 04/14/2004 | EP1015490B1 No-modified hemoglobins and uses therefor |
| 04/14/2004 | EP0979240B1 Serine protease inhibitors |
| 04/14/2004 | EP0883406B1 Use of il-7 for treating auto-immune diseases and insulin-dependent diabetes mellitus in particular |
| 04/14/2004 | EP0765392B1 Interleukin-5 specific recombinant antibodies |
| 04/14/2004 | EP0748213B1 Methods and compositions for pulmonary delivery of insulin |
| 04/14/2004 | EP0729975B1 Ecdn protein and dna coding for the same |
| 04/14/2004 | EP0724561B1 Calcium receptor-active arylalkyl amines |
| 04/14/2004 | EP0707487B1 Methods and pharmaceutical compositions useful for treating neurological disorders |
| 04/14/2004 | CN1489628A Compounds and methods for treatment and diagnosis of chlamydial infection |
| 04/14/2004 | CN1489576A Cannabinod receptor ligands |
| 04/14/2004 | CN1489477A Conjugates of glycosylated/galactosylated peptide, bifunctional linker and nucleotidic monomers/polymers, and related compositions and method of use |
| 04/14/2004 | CN1489476A Method of preparing biological materials and preparation produced using same |
| 04/14/2004 | CN1489471A Educated NKT cells and their uses in the treatment of immune-related disorder |
| 04/14/2004 | CN1488757A Human vasular endothelial growth factor recombinant adenovirus and preparing method use thereof |
| 04/14/2004 | CN1488641A Polypeptide medicine for inhibiting SARS coronavirus, and derivatives and use thereof |
| 04/14/2004 | CN1488402A Novel medicinal use of proteinase inhibior for preventing and curing lang disease |
| 04/14/2004 | CN1488400A Preparation for preventing and curing endometritis for dairy cattle and preparing method thereof |
| 04/14/2004 | CN1488399A Medicinal use of agkistrodon acutus thrombase for treating hemorrhagic disease |
| 04/14/2004 | CN1488398A Instant freeze-dried fibriogen preparation with anti dry heat treatment |
| 04/14/2004 | CN1488353A Composition for treating ischemic disease |
| 04/14/2004 | CN1488331A Ultra porous hydrogel complex substance, preparing method and use in pharmaceutics thereof |
| 04/14/2004 | CN1145701C Recombinant glucokinase as thrombolytic medicine |
| 04/14/2004 | CN1145696C Antifungal proteins |
| 04/14/2004 | CN1145695C Antifungal protein |
| 04/14/2004 | CN1145694C Novel human thrombopoietin mutein |
| 04/14/2004 | CN1145693C Amino-terminally truncated MCP-2 as chemokine antagnosits |
| 04/14/2004 | CN1145641C Monomeric insulin analog formulations |
| 04/14/2004 | CN1145637C Thio-substituted peptides as inhibitors for metalloproteinases and tnfliberation |
| 04/14/2004 | CN1145497C Enterogastric external nutrition composition and its pharmaceutic use thereof |
| 04/14/2004 | CN1145496C Novel formulation for peptide release |
| 04/14/2004 | CN1145493C Materials for preventing arteriosclerosis |
| 04/13/2004 | US6721955 Method and system for providing a customized media list |
| 04/13/2004 | US6721595 Percutaneous absorption promoters for electroporation |
| 04/13/2004 | US6720472 Therapy for use in the treatment of obesity; obtain mammal, administer dietetic modulating agent, monitor adjustment in weight |
| 04/13/2004 | US6720433 Ethylamine derivatives |
| 04/13/2004 | US6720415 S-ribosylhomocysteine to homocysteine; bacterial genes involved in biosynthesis of the signaling molecule; bacterial autoinducer-2 signaling molecule; luminescence in the vibrio harveyi signaling system 2 bioassay; luxq luminescence genes |
| 04/13/2004 | US6720413 Methods and compositions for diagnosis and treatment of cancer |
| 04/13/2004 | US6720410 Nucleic acids encoding enamel matrix related polypeptides |
| 04/13/2004 | US6720409 Anti-human influenza virus antibody |
| 04/13/2004 | US6720407 Method for administering insulinotropic peptides |
| 04/13/2004 | US6720335 Sulfonamide inhibitors of aspartyl protease |
| 04/13/2004 | US6720330 Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
| 04/13/2004 | US6720323 Colchinol derivatives as angiogenesis inhibitors |
| 04/13/2004 | US6720311 To cause apoptosis in colon cancer and prostate cancer cells |
| 04/13/2004 | US6720306 Drug delivery, antitumor agents |
| 04/13/2004 | US6720305 Ramoplanin (inn) is a known member of the cyclic peptide antibiotics more precisely known as glycolipodepsipeptides |
| 04/13/2004 | US6720304 Conjugate comprising a folic acid antagonist and a carrier |
| 04/13/2004 | US6720182 Alternative splice variants of CD40 |
| 04/13/2004 | US6720180 Epsin 3, a novel protein closely related to, but distinct from previously described epsins. this protein plays an important role in activated epithelial cells during tissue morphogenesis. |
| 04/13/2004 | US6720175 Mediating receptor-activated or ion channel-mediated intracellular calcium mobilization or concentration. |
| 04/13/2004 | US6720159 88KDA tumorigenic growth factor and antagonists |
| 04/13/2004 | US6720158 Splice variants of BRCA1 |
| 04/13/2004 | US6720146 Nucleotide sequences coding polypeptide for use in the treatment, diagnosis and prevention of ovarian cancer |
| 04/13/2004 | US6720014 Culturing escherichia coli; genetic engineering and expression |
| 04/13/2004 | US6720009 Matrix protein compositions for treating infection |
| 04/13/2004 | US6719992 Non-aqueous surfactant-containing formulations for extended release of somatotropin |
| 04/13/2004 | US6719990 Non-aqueous injectable formulations for extended release of somatotropin |
| 04/13/2004 | US6719986 Fermented by microorganisms; skin disorders; aging and wrinkle resistance |
| 04/13/2004 | US6719982 Transcriptional activation is prevented; nervous system disorders; gene therapy; genetic engineering and expression |
| 04/13/2004 | US6719978 Virus-like particles for the induction of autoantibodies |
| 04/13/2004 | US6719977 Administering relaxin and/or gamma- interferon peptides to reduce tissue tensile modulus-reducing property |
| 04/13/2004 | US6719976 Administering monomolecular multi-epitope peptide prepared by binding t-cell epitope regions derived from different allergens |
| 04/13/2004 | US6719974 Heat shock protein-based vaccines and immunotherapies |
| 04/13/2004 | US6719973 Lipopolysaccharide (lps)-binding peptide; septic shock treatment |
| 04/13/2004 | US6719972 Induce antigen specific apoptosis in activated t cells; ligands with monoclonal anti-ctla4 antibody that binds to an epitope of ctla4 |
| 04/13/2004 | US6719971 Method for making humanized antibodies |
| 04/13/2004 | US6719969 High speed hepatocyte proliferation and liver regeneration after injury caused by acetominophen overdose or surgery; side effect reduction of gene therapy |
| 04/13/2004 | US6719968 For therapy of tendinitis, or other tendon or ligament defect |
| 04/13/2004 | US6718986 Mixed chimerism and tolerance |
| 04/13/2004 | CA2322963C Methods to increase white blood cell survival after chemotherapy |
| 04/13/2004 | CA2291608C Neurotrophic factor receptors |
| 04/13/2004 | CA2261150C Methods for purifying nucleic acids |
| 04/13/2004 | CA2195076C Process for modifying the stability of antibodies |
| 04/11/2004 | CA2403313A1 Potent t cell modulating molecules |
| 04/08/2004 | WO2004029631A2 Method for identifying bhs-specific proteins and fragments thereof |
| 04/08/2004 | WO2004029617A2 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a (pde11a) |
| 04/08/2004 | WO2004029287A2 Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer |
| 04/08/2004 | WO2004029281A2 Methods and compositions for rnai mediated inhibition of viral gene expression in mammals |
| 04/08/2004 | WO2004029253A2 Nucleic acid sequences coding for proteolytic enzymes in the form of specific proteases, corresponding polypeptides and use of the same |
| 04/08/2004 | WO2004029248A1 Tumor antigen protein and utilization thereof |
| 04/08/2004 | WO2004029246A2 Integrase cofactor |
| 04/08/2004 | WO2004029229A2 Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands |
| 04/08/2004 | WO2004029218A2 Receptors and membrane-associated proteins |
| 04/08/2004 | WO2004029215A2 Conditional gene expression using rnai |
| 04/08/2004 | WO2004029213A2 Compositions and methods for delivery of short interfering rna and short hairpin rna |
| 04/08/2004 | WO2004029212A2 In vivo gene silencing by chemically modified and stable sirna |
| 04/08/2004 | WO2004029205A2 Structural and cytoskeleton-associated proteins |
| 04/08/2004 | WO2004029201A2 Peptide derivative fusion inhibitors of hiv infection |
| 04/08/2004 | WO2004029200A2 Method of enhancing proliferation and/or hematopoietic differentiation of stem cells |
| 04/08/2004 | WO2004029197A2 Co-stimulatory molecules |